Keywords: b-ms, enters, deal, worth, up, 12b, co-develop
B-MS enters deal worth up to $1.12B to co-develop ZymoGenetics' PEG-INF lambda
Article | 19 January 2009
US drug major Bristol-Myers Squibb has agreed to develop a Phase Ib-stage hepatitis C drug made by US firm ZymoGenetics ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- Elan makes "transformational" acquisitions and a divestment
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- CIS countries prepare for the introduction of drug reimbursement schemes
- Greek research-based drugmaker group AIFD challenges generics assumptions in Draft Patent Law
